...
首页> 外文期刊>Journal of Clinical Microbiology >A chromosomal Borrelia burgdorferi gene encodes a 22-kilodalton lipoprotein, P22, that is serologically recognized in Lyme disease.
【24h】

A chromosomal Borrelia burgdorferi gene encodes a 22-kilodalton lipoprotein, P22, that is serologically recognized in Lyme disease.

机译:伯氏疏螺旋体的染色体基因编码一种22千达尔顿脂蛋白P22,该蛋白在血清学上被识别为莱姆病。

获取原文
           

摘要

We describe the isolation of the gene encoding a 22-kDa antigen from Borrelia burgdorferi, the etiologic agent of Lyme disease. The p22 gene is 582 nucleotides in length and encodes a protein of 194 amino acids with a predicted molecular mass of 21.8 kDa. The leader signal sequence of P22 consists of a positively charged short amino terminus, a central hydrophobic domain, and at the carboxyl terminus, a cleavage site that is presumably recognized and cleaved by a B. burgdorferi signal peptidase. P22 has 98.5% homology with the recently described B. burgdorferi protein IpLA7. P22 is processed as a lipoprotein, as demonstrated by [3H]palmitate labeling. Pulsed-field gel electrophoresis showed that p22, like LA7, is localized to the linear chromosome of B. burgdorferi. Examination of sera from patients with Lyme disease revealed that antibodies to P22 are rarely detected in patients with early-stage disease characterized by erythema migrans (2 of 20), and 35% of the patients with late-stage disease characterized by arthritis (9 of 26) developed antibodies to P22. Sera from patients with syphilis did not react with P22. When patients with late-stage disease were tested for their antibody reactivities to four other outer surface proteins (OspA), OspB, OspE, and OspF), 75% of these patients responded to P22 or to one or more outer surface proteins.
机译:我们描述了从伯氏疏螺旋体,莱姆病的病原体编码22 kDa抗原的基因的分离。 p22基因的长度为582个核苷酸,编码194个氨基酸的蛋白质,预测分子量为21.8 kDa。 P22的前导信号序列由带正电荷的短氨基末端,中央疏水结构域和在羧基末端的切割位点组成,该切割位点可能被伯氏疏螺旋体信号肽酶识别和切割。 P22与最近描述的伯氏疏螺旋体蛋白IpLA7具有98.5%的同源性。如[3H]棕榈酸酯标记所示,P22被加工为脂蛋白。脉冲场凝胶电泳显示,p22与LA7一样,位于B. burgdorferi的线性染色体上。对莱姆病患者的血清进行检查后发现,在以红斑性红斑为特征的早期疾病(20分之2)和以关节炎为特征的晚期疾病的患者(3分9)中,很少检测到P22抗体。 26)开发了针对P22的抗体。梅毒患者的血清与P22无反应。当对患有晚期疾病的患者进行针对其他四种外表面蛋白(OspA),OspB,OspE和OspF的抗体反应性测试时,这些患者中有75%对P22或一种或多种外表面蛋白有反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号